Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)

A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were me...

Descripción completa

Detalles Bibliográficos
Autores principales: Convertino, Matteo, Church, Timothy R, Olsen, Geary W, Liu, Yang, Doyle, Eddie, Elcombe, Clifford R, Barnett, Anna L, Samuel, Leslie M, MacPherson, Iain R, Evans, Thomas R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Pbpk Modeling for Pfoa Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920327/
https://www.ncbi.nlm.nih.gov/pubmed/29462473
http://dx.doi.org/10.1093/toxsci/kfy035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920327/
https://www.ncbi.nlm.nih.gov/pubmed/29462473
http://dx.doi.org/10.1093/toxsci/kfy035

Ejemplares similares